FDA Expands EVO ICL Age Range to 60, Unlocking 8M New Patients
FDA expanded Staar Surgical’s EVO/EVO+ ICL age indication from 21–45 to 21–60 years, potentially adding 8 million refractive patients. Three-year clinical data on 629 eyes showed a safety index of 1.25, zero pupillary block cases and only 0.16% anterior subcapsular cataract incidence.
1. FDA Approval and Market Impact
The FDA expanded the EVO/EVO+ Visian ICL age indication from 21–45 to 21–60 years, unlocking a potential additional 8 million refractive patients in the U.S. The change may drive increased ICL implant volumes and boost Staar Surgical's revenue trajectory.
2. Three-Year Clinical Trial Safety
In a three-year clinical trial of 629 eyes, the EVO ICL achieved a safety index of 1.25, with no pupillary block or pigment dispersion events and only a 0.16% incidence of anterior subcapsular cataract, reinforcing its long-term safety profile.
3. Patient Demand and Market Expansion
Recent data show over half of U.S. vision correction patients are seeking alternatives to LASIK, with EVO ICL leading procedures for those with −8.0 diopters or higher as laser-based surgeries decline. The age expansion positions EVO ICL to capitalize on this shift in patient preferences.
4. Stock Performance and Analyst Outlook
Staar Surgical stock rose 2.28% in premarket trading, trading below key moving averages with an RSI of 22.35 suggesting oversold conditions. The company reports earnings on March 3 with analysts forecasting EPS of $0.12 on $75.25 million revenue and holding an average target of $27.30.